GeneNews secures $2 million for development of prostate biomarkers

TORONTO, Aug. 13 /CNW/ - GeneNews Limited (TSX: GEN), a company focused on developing simple blood-based biomarker tests for the early detection of diseases and personalized health management, today announced it has signed an agreement with an Asian Biomedical consortium to develop blood-based biomarkers for the detection and management of prostate diseases.

Under the agreement, the consortium will provide US$2 million to GeneNews to conduct the work required to identify and validate biomarkers related to prostate disease using its proprietary Sentinel Principle(TM) and Discovery Funnel(TM) technologies. If a biomarker panel is successfully validated, GeneNews will then develop and commercialize a prostate disease test based on these biomarkers to be known as ProstateSentry(TM). All intellectual property generated in the identification and validation of prostate disease biomarkers shall remain vested in GeneNews and the consortium shall be entitled to receive certain royalties from the commercial sales of ProstateSentry.

"As our population ages, the incidence of prostate diseases including prostate cancer has been growing significantly. In addition, current methods of assessing prostate health are either invasive or provide information that is not consistently actionable," said K. Wayne Marshall, MD, PhD, President and Chief Executive Officer of GeneNews. "While our primary focus is currently on the development of our lead colon cancer product, ColonSentry(TM), this non-dilutive investment will allow us accelerate the development of a second product in our Sentry(TM) pipeline. Given the results we have generated to date in prostate cancer, we are well positioned to deliver on these objectives."

In June 2006, GeneNews reported results from a study that identified a set of blood biomarkers which were able to distinguish patients with aggressive forms of prostate cancer from controls. The study abstract, entitled "Blood-based biomarkers for detecting aggressive prostate cancer at time of biopsy," was presented at the 2006 American Society of Clinical Oncology (ASCO) Annual Meeting.

About GeneNews

GeneNews is focussed on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' first product in development, ColonSentry(TM), is a blood-based test that can detect colon cancer. For more information on GeneNews, visit www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

SOURCE GeneNews Limited

For further information: For further information: Dr. K. Wayne Marshall, President & CEO, (416) 650-0060 x234, wmarshall@genenews.com; James Smith, (416) 815-0700 x229, jsmith@equicomgroup.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890